Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Discussion session - Sarcoma

5261 - A phase 2, multicenter study of the EZH2 inhibitor tazemetostat in adults: (epithelioid sarcoma cohort) (NCT02601950)


22 Oct 2018


Poster Discussion session - Sarcoma


Cytotoxic Therapy;  Clinical Research

Tumour Site



Mrinal Gounder


Annals of Oncology (2018) 29 (suppl_8): viii576-viii595. 10.1093/annonc/mdy299


M. Gounder1, P. Schöffski2, V. Villalobos3, G. Cote4, R. Chugh5, T.W. Chen6, T. Jahan7, E.T. Loggers8, A. Italiano9, A. Gupta10, M. Agulnik11, S. Attia12, R.L. Jones13, B.A. Van Tine14, G.D.D. Demetri15, M. Roche16, I. Sapir17, S. Daigle17, A. Clawson17, S. Stacchiotti18

Author affiliations

  • 1 Division Of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, 10022 - New York/US
  • 2 Department Of General Medical Oncology, University Hospitals Leuven, Leuven/BE
  • 3 Medical Oncology, University of Colorado, Denver/US
  • 4 Medical Oncology, Massachusetts General Hospital, Boston/US
  • 5 Medical Oncology, Michigan Medicine Comprehensive Cancer Center, Ann Arbor/US
  • 6 Medical Oncology, National Taiwan University Hospital, Taipei City/TW
  • 7 Medical Oncology, University of California, San Francisco/US
  • 8 Clinical research Division, Fred Hutchinson Cancer Research Center, Seattle/US
  • 9 Early Phase Trials Unit, Institute Bergonié, Bordeaux/FR
  • 10 Department Of Hematology And Oncology, Princess Margaret Hospital, Toronto/CA
  • 11 Hematology/ Oncology, Northwestern Memorial Hospital, Chicago/US
  • 12 Oncology, Mayo Clinic, Jacksonville/US
  • 13 Medical Oncology, The Royal Marsden Hospital and Institute for Cancer Research, London/GB
  • 14 School Of Medicine, Washington University in St. Louis, St. Louis/US
  • 15 Ludwig Center At Harvard Medical School, Dana-Farber Cancer Institute, Boston/US
  • 16 Clinical, Epizyme, 02139 - Cambridge/US
  • 17 Clinical, Epizyme, Cambridge/US
  • 18 Department Of Medical Oncology, Fondazione IRCCS Istituto Nazioale Tumori, Milan/IT


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 5261


Epithelioid sarcoma (ES) is a rare soft tissue sarcoma with current treatments for metastatic disease having limited activity in terms of durable clinical benefit and significant toxicities. Loss of INI1, a subunit of the SWI/SWF complex and a negative regulator of EZH2, occurs in over 90% of ES tumors and is a characteristic diagnostic feature of ES. EZH2, a methyltransferase in PRC2, is a known oncogenic driver. In INI1 deficient preclinical models, EZH2 inhibition reprograms pathways related to abnormal cell growth, leading to cell death or differentiation and subsequent tumor control and regression. Tazemetostat, a potent, selective, orally available inhibitor of EZH2, has shown clinical activity in malignant rhabdoid tumor and ES patients (pts) in phase 1. We report interim phase 2 safety and efficacy of tazemetostat in pts with ES.


This was a phase 2, multicenter, open-label, single arm study of tazemetostat (800 mg PO BID) in adults with advanced disease whose tumors harbor INI1 loss (7 different tumor type cohorts). For the ES cohort, the primary endpoint was objective response rate (ORR) by RECIST 1.1. Secondary endpoints included disease control rate (DCR; confirmed CR or PR of any duration or SD lasting ≥32 weeks), safety/tolerability, and duration of response.


As of April 6, 2018, in 62 ES pts (63% male, median age 34 years, median of 1 prior systemic therapy), there were 8 confirmed PRs with an ORR of 13% and DCR of 26%. Additionally, 35 pts had a best response of SD with 7 pts ongoing. Individual PR durations (weeks) were: 8+, 8+, 24+, 24, 32+, 40, 41, and 70 + (+ indicates ongoing response). No pts discontinued due to adverse events (AEs); 2 pts had dose reductions due to AEs. AEs (any grade) included fatigue (39%), nausea (32%), and cancer pain (31%). Treatment-related AEs ≥Grade 3 reported in ≥ 2 pts were anemia (5%) and decreased weight (3%).


In this study, the largest prospective clinical trial of ES to date, tazemetostat showed promising single agent activity, resulting in durable confirmed responses, a DCR of 26%, and favorable safety. As these tumors are aggressive with limited response to current treatment, tazemetostat represents a potential therapeutic option warranting further investigation.

Clinical trial identification


Legal entity responsible for the study

Epizyme, Inc.


Epizyme, Inc.

Editorial Acknowledgement

Third-party writing assistance was provided by Rob Steger, PhD, and Andrea Eckhart, PhD, of Ashfield Healthcare Communications (a UDG Healthcare plc company), and supported by Epizyme, Inc.


M. Gounder: Paid consultant and board member: Epizyme; Medical advisory board: Karyopharm; Advisory board and honorarium: Daiichi, Tracon; Honorarium: Amgen. P. Schöffski, B.A. van Tine: Institutional honorarium for advisory function: Epizyme. R. Chugh: Research funding, scientific advisor/consultant: Epizyme. T.W-W. Chen: Research fund, honorarium: Eisai; Honorarium: Novartis. T. Jahan: Research funding: Aduro Biotech, Acerta Pharma, AstraZeneca/MedImmune, Lilly, Boehringer Ingelheim, Kadmon, BMS, Polaris, Epizyme. A. Italiano: Advisory board consulting: Epizyme. M. Agulnik: Consulting/advisory: Janssen, Eisai, Novartis, Lilly; Speakers' bureau: Eisai, Bristol-Myers Squibb. R.L. Jones: Consultant: Adaptimmune, Blueprint, Clinigen, Eisai, Epizyme, Daichii, Deciphera, Immunedesign, Lilly, Merck, Pharmamar. G.D.D. Demetri: Bayer, Novartis, Pfizer, Janssen Oncology, Ignyta, Loxo Oncology, AbbVie, Epizyme, Adaptimmune - Research support to Dana-Farber for GD as PI in clinical trial agreements in DFCI sarcoma unit; Novartis, Pfizer, EMD Serono, Sanofi Oncology, Janssen Oncology, Ignyta, Loxo Oncology, Mirati Therapeutics, Epizyme, PharmaMar, Daiichi-Sankyo, WIRB Copernicus Group, ZioPharm, Polaris Pharmaceuticals - consultant/fees; Novartis - patent licensed from Dana-Farber with royalty paid to Dana-Farber; Blueprint Medicines, Merrimack Pharmaceuticals - Member, board of directors, member, scientific advisory board; Blueprint Medicines, Merrimack Pharmaceuticals, G1, Caris Life Sciences, Champions Oncology - consultant advisory board, consulting fees and equity (minor stake, public or non-public); Bessor Pharmaceuticals - consultant, equity (minor stake, non-public). M. Roche, I. Sapir, S. Daigle, A. Clawson: Paid employee and stock: Epizyme. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.